SEC Company Response from SUNESIS PHARMACEUTICALS INC (VIRX) (CIK 0001061027) (VIRX) — Sep 27, 2005
SUNESIS PHARMACEUTICALS INC (VIRX) (CIK 0001061027)
Date: Sept. 27, 2005 · CIK: 0001061027 · Accession: 0001104659-05-045862
AI Filing Summary & Sentiment
File numbers found in text: 333-121646
Letter
[SG Cowen & Co., LLC Letterhead]
September 27, 2005
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 03-08
Washington, D.C.
Attention: Mr. Zafar Hasan Esq.
Re: Sunesis Pharmaceuticals, Inc.
Registration Statement on Form S-1 (File No. 333-121646)
Ladies and Gentlemen:
As representative of the undersigned underwriters of the proposed initial public offering of up to 6,000,000 shares of common stock of Sunesis Pharmaceuticals, Inc., we hereby represent to the Staff of the U.S. Securities and Exchange Commission that the normal channels of communications between the underwriters and potential purchasers are being and would be used to inform such potential purchasers of (1) the change in the offering price, (2) the indications of interest submitted by the Company’s existing stockholders and (3) the amount of the deemed dividend prior to confirming sales. In addition, a copy of the final prospectus will accompany each confirmation notice.
Very truly yours,
LEHMAN BROTHERS INC.
Show Raw Text
CORRESP 1 filename1.htm [SG Cowen & Co., LLC Letterhead] September 27, 2005 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 03-08 Washington, D.C. 20549 Attention: Mr. Zafar Hasan Esq. Re: Sunesis Pharmaceuticals, Inc. Registration Statement on Form S-1 (File No. 333-121646) Ladies and Gentlemen: As representative of the undersigned underwriters of the proposed initial public offering of up to 6,000,000 shares of common stock of Sunesis Pharmaceuticals, Inc., we hereby represent to the Staff of the U.S. Securities and Exchange Commission that the normal channels of communications between the underwriters and potential purchasers are being and would be used to inform such potential purchasers of (1) the change in the offering price, (2) the indications of interest submitted by the Company’s existing stockholders and (3) the amount of the deemed dividend prior to confirming sales. In addition, a copy of the final prospectus will accompany each confirmation notice. Very truly yours, LEHMAN BROTHERS INC. SG COWEN & CO., LLC NEEDHAM & COMPANY, LLC BY: SG COWEN & CO., LLC BY: /S/ GRAHAM POWISS Graham Powiss, Managing Director